University Clinic in Dresden, Germany to commence testing Lipid inCode® polygenic testing to prevent Cardiovascular Disease Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease, announces today its collaboration with the University Clinic Dresden, Department of Internal Medicine and Department of Human Genetics, based in Dresden, Germany to use its Lipid inCode®

NHS earmarks budget to expand GENinCode’s LIPID inCode® polygenic testing to prevent Cardiovascular Disease Oxford, UK. GENinCode Plc (AIM: GENI), the genetics company focused on the prevention of cardiovascular disease, announces the expansion of its collaboration with the Academic Health Science Network for the North East and North Cumbria (“AHSN NENC”) to use the LIPID inCode® polygenic test in Primary

FULL TIME/PART TIME CLINICAL SCIENTIST  – GENETIC TESTING, IN-VITRO DIAGNOSTIC. SALARY NEG DEPENDANT UPON EXPERIENCE + BENEFITS We are a leading Genetic Testing organisation seeking an experienced Clinical Scientist  to join our team in Barcelona on a permanent, full time/part time basis, with flexible working patterns available. GENinCode is a Cutting-edge Biotech company specialized in Predictive  Genetics with a portfolio focused

Oxford, UK. GENinCode Plc (AIM: GENI), the genetics company focused on the prevention of cardiovascular disease (“CVD”), announces the Amercian Medical Asscoiation (AMA) grant of a Current Procedural Terminology (CPT) Proprietary Laboratory Analyses (PLA) code for its CARDIO inCode-SCORE (“CIC-SCORE”) polygenic test for the risk assessment of Coronary Heart Disease. The new code 0401U, has been approved and published by

First pilot test in Spanish Primary Care, resulting from an agreement between the Predictive Genetics company GENinCode and the Extremadura Public Healthcare, to improve cardiovascular disease (CVD) prevention. CARDIO inCode® is a world leading Personalised Medicine test, with significant scientific and clinical evidence which has been developed over the past 15 years and validated in over 80.000 patients. In 2019,

FULL / PART TIME (Neg) HCPC REGISTERED CLINICAL SCIENTIST (GENETICS)  – GENETIC TESTING, BIOTECH ORGANISATION, SALARY NEG DEPENDANT UPON EXPERIENCE + BENEFITS We are a leading Genetic Testing organisation seeking an experienced HCPC Registered Clinical Scientist (Genetics) to join our team on a permanent, Part-time or full-time basis (Neg).   THE ROLE HCPC registered Clinical Scientist. First or second-class BSc honours

First pilot test in Spanish Primary Care, resulting from an agreement between the Predictive Genetics company GENinCode and the Extremadura Health Service, to improve cardiovascular disease (CVD) prevention. CARDIO inCode® is a world leading Personalised Medicine test, with significant scientific and clinical evidence which has been developed over the past 15 years and validated in over 80.000 patients. In 2019,

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease (“CVD”), announces California state licensing approval and CLIA certification of its Irvine laboratory in California, enabling the provision of its products for the risk assessment of CVD to patients across 49 states in the United States.   The approval of the California state

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo. https://youtu.be/mB7xgRcpgsc

Oxford, UK. GENinCode Plc (AIM: GENI), the predictive genetics company focused on the prevention of cardiovascular disease (“CVD”) and risk of ovarian cancer (“OC”), announces jointly with the British Medical Journal (“BMJ”), the ALDO publication in the Journal of Medical Genetics. ALDO is an NHS national pilot surveillance programme for women with pathogenic germline variants in BRCA1 and BRCA2 inherited